Should I buy or sell Cyclo Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclo Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CYTH shares. View CYTH analyst ratings or view top-rated stocks .

What is Cyclo Therapeutics' stock price target for 2024?

1 Wall Street research analysts have issued 12 month price objectives for Cyclo Therapeutics' stock. Their CYTH share price targets range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 233.3% from the stock's current price. View analysts price targets for CYTH or view top-rated stocks among Wall Street analysts .

How have CYTH shares performed in 2024?

Cyclo Therapeutics' stock was trading at $1.59 at the beginning of the year. Since then, CYTH shares have decreased by 24.5% and is now trading at $1.20. View the best growth stocks for 2024 here .

Are investors shorting Cyclo Therapeutics?

Cyclo Therapeutics saw a drop in short interest in March. As of March 31st, there was short interest totaling 45,600 shares, a drop of 59.5% from the March 15th total of 112,600 shares. Based on an average daily trading volume, of 115,000 shares, the short-interest ratio is currently 0.4 days. Approximately 0.4% of the company's stock are short sold. View Cyclo Therapeutics' Short Interest .

When is Cyclo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CYTH earnings forecast .

How were Cyclo Therapeutics' earnings last quarter?

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) announced its quarterly earnings results on Monday, March, 18th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $0.31 million for the quarter. Cyclo Therapeutics had a negative net margin of 1,864.03% and a negative trailing twelve-month return on equity of 4,506.97%.

How do I buy shares of Cyclo Therapeutics?

Shares of CYTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CYTH

Cyclo Therapeutics (CYTH) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free CYTH Stock Alerts

$1.19

-0.01 (-0.83%)

(As of 11:28 AM ET)

Compare

Today's Range: $1.17
▼
$1.19
50-Day Range: $1.20
▼
$1.76
52-Week Range: $0.68
▼
$2.57

Volume: 4,413 shs
Average Volume: 105,144 shs
Market Capitalization: $34.18 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Get Cyclo Therapeutics alerts:

Cyclo Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 233.3% Upside
$4.00 Price Target
Short Interest: Healthy
0.36% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.47 out of 5 stars

Medical Sector

347th out of 918 stocks

Biological Products, Except Diagnostic Industry

49th out of 154 stocks

3.5

Analyst's Opinion

Consensus Rating
Cyclo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Cyclo Therapeutics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.36% of the float of Cyclo Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Cyclo Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cyclo Therapeutics has recently decreased by 59.50%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Cyclo Therapeutics does not currently pay a dividend.
Dividend Growth
Cyclo Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CYTH.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Cyclo Therapeutics this week, compared to 0 articles on an average week.
MarketBeat Follows
1 people have added Cyclo Therapeutics to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cyclo Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
29.78% of the stock of Cyclo Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
68.55% of the stock of Cyclo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Cyclo Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cyclo Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cyclo Therapeutics has a P/B Ratio of 5.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Weiss Ratings

The only accurate crypto trading system I know …

Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.

Here's what our expert says you should buy before April 14.

About Cyclo Therapeutics Stock (NASDAQ:CYTH)

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

CYTH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CYTH Stock News Headlines

April 13, 2024 | americanbankingnews.com

Comparing Cyclo Therapeutics (NASDAQ:CYTH) & Opthea (NASDAQ:OPT)

April 10, 2024 | finance.yahoo.com

Pleasing Signs As A Number Of Insiders Buy Cyclo Therapeutics Stock

April 19, 2024 | The Bull Report (Ad)

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

March 19, 2024 | investorplace.com

CYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q4 2023

March 18, 2024 | businesswire.com

Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

March 14, 2024 | finance.yahoo.com

Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

March 14, 2024 | businesswire.com

Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's Disease

February 2, 2024 | finance.yahoo.com

Cyclo Therapeutics, Inc. (CYTH)

April 19, 2024 | The Bull Report (Ad)

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

January 29, 2024 | markets.businessinsider.com

Cyclo Therapeutics Gets Notice Of Allowance For Patent Regarding Treatment Of Alzheimer's Disease

January 29, 2024 | finance.yahoo.com

Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office

January 3, 2024 | morningstar.com

Cyclo Therapeutics Inc CYTH

December 28, 2023 | msn.com

Cytosorbents, Cyclo Therapeutics among healthcare movers

December 18, 2023 | finance.yahoo.com

Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1

December 14, 2023 | finance.yahoo.com

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

November 29, 2023 | businesswire.com

APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied ...

November 21, 2023 | finance.yahoo.com

Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024

November 15, 2023 | msn.com

Cyclo Therapeutics reports Q3 results

November 15, 2023 | finance.yahoo.com

Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

November 10, 2023 | seekingalpha.com

WISH, REAL and PIXY among mid-day movers

November 2, 2023 | finance.yahoo.com

Several Insiders Invested In Cyclo Therapeutics Flagging Positive News

October 30, 2023 | finance.yahoo.com

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

October 23, 2023 | finance.yahoo.com

Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million

October 5, 2023 | finance.yahoo.com

Cyclo Therapeutics to Present at 8th Annual Dawson James Conference

September 21, 2023 | tmcnet.com

CYTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cyclo Therapeutics, Inc. Is Fair to Shareholders

September 21, 2023 | finance.yahoo.com

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

August 15, 2023 | finance.yahoo.com

Cyclo Therapeutics Reports Second Quarter 2023 Financial Results

See More Headlines

Receive CYTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/18/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:CYTH
CUSIP: N/A
CIK: 922247
Web: www.ctd-holdings.com
Phone: (386) 418-8060
Fax: 321-244-8351
Employees: 8
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $4.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +233.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.31)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,060,000.00
Net Margins: -1,864.03%
Pretax Margin: -1,864.03%
Return on Equity: -4,506.97%
Return on Assets: -290.83%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.45
Quick Ratio: 1.42

Sales & Book Value

Annual Sales: $1.08 million
Price / Sales: 31.91
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.21 per share
Price / Book: 5.71

Miscellaneous

Outstanding Shares: 28,720,000
Free Float: 20,164,000
Market Cap: $34.46 million
Optionable: No Data
Beta: -0.15

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. N. Scott Fine (Age 67)
CEO & Director
Comp: $569.92k
Mr. C. E Strattan (Age 78)
Founder & Director
Mr. Joshua M. Fine (Age 42)
CFO & Secretary
Comp: $421.17k
Mr. Michael Eric Lisjak (Age 50)
Global Head of Regulatory Affairs & Senior VP of Business Development
Comp: $430.4k
Dr. Jeffrey L. Tate Ph.D. (Age 66)
COO, Chief Quality Officer & Director
Comp: $255.14k
Ms. Lori McKenna
Global Head of Patient Advocacy
Dr. Karen Mullen FFPM
Interim Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CYTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Cyclo Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclo Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CYTH shares.
View CYTH analyst ratings or view top-rated stocks.
What is Cyclo Therapeutics' stock price target for 2024?: 1 Wall Street research analysts have issued 12 month price objectives for Cyclo Therapeutics' stock. Their CYTH share price targets range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 233.3% from the stock's current price.
View analysts price targets for CYTH or view top-rated stocks among Wall Street analysts.
How have CYTH shares performed in 2024?: Cyclo Therapeutics' stock was trading at $1.59 at the beginning of the year. Since then, CYTH shares have decreased by 24.5% and is now trading at $1.20.
View the best growth stocks for 2024 here.
Are investors shorting Cyclo Therapeutics?: Cyclo Therapeutics saw a drop in short interest in March. As of March 31st, there was short interest totaling 45,600 shares, a drop of 59.5% from the March 15th total of 112,600 shares. Based on an average daily trading volume, of 115,000 shares, the short-interest ratio is currently 0.4 days. Approximately 0.4% of the company's stock are short sold.
View Cyclo Therapeutics' Short Interest.

When is Cyclo Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our CYTH earnings forecast.
How were Cyclo Therapeutics' earnings last quarter?: Cyclo Therapeutics, Inc. (NASDAQ:CYTH) announced its quarterly earnings results on Monday, March, 18th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $0.31 million for the quarter. Cyclo Therapeutics had a negative net margin of 1,864.03% and a negative trailing twelve-month return on equity of 4,506.97%.
How do I buy shares of Cyclo Therapeutics?: Shares of CYTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CYTH) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial